StandoutStocks.com: StandoutStocks.com "Stocks that Standout" today ..

Tag : polyurethane sole

Released : Tuesday, July 22, 2008 11:53 AM
RDATE:22072008
July 22, 2008 StandoutStocks.com "Stocks that Standout" today are:EAGLE ROCK ENTERPRISES, INC. (PINKSHEETS: EREI), Force Energy Corp.(OTCBB: FORC), GeoVax Labs, Inc. (OTCBB: GOVX), HybredInternational, Inc.(OTCBB: HYII), Invicta Group Inc. (OTCBB: IVIT),Rim Semiconductor Company (OTCBB: RSMI),
Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER atwww.Standoutstocks.com
Jul 22, 2008 -- EAGLE ROCK ENTERPRISES, INC. (PINKSHEETS: EREI),(EAGLE ROCK), announced today that the Company has signed a letterof intent to acquire MPD, a distributing and warehousing company.MPD maintains a national logistics base. Their experience ininternational shipping will provide EAGLE ROCK with the necessarysupport systems for current and future business development.
MPD will provide a strategic plan to implement EAGLE ROCK'Sdomestic and international marketing programs. MPD is the key linkin the vertical integration process that allows EAGLE ROCK toproduce and sell products worldwide, and in return, purchase fromforeign markets to distribute in the United States.
Jul 22, 2008 -- Force Energy Corp. (OTCBB: FORC) (hereafter"Force", "the Company") announces a 20% working interest in theHayter Well (10D Hayter 10-8-40-1 W4M) located in Alberta, Canada.The well was spudded in January 2007 and drilled to a total depth.The well logs revealed a gas zone of 4 to 5 meters of thickness ina shallow zone and a heavy oil pay zone of 2 meters of thickness inthe target Dina Sand zone. Although the results in the Dina sandwere lower than expected and a decision was made to case the wellin 2007, at today's prices, the Hayter could produce an economicwell.
County Line Energy completed a $650,000 3D seismic program coveringnine sections of land in pursuit of a potential multi well heavyoil drilling opportunity. The geological model was based oninterpretation from a previous well, which produced 16,000 barrelsof heavy oil. The seismic program was designed to determine whetherthe structure found in this well existed to a larger extent on thesubject property. The 3D seismic revealed an extremely largeanomaly with similar characteristics. The nature of this largeanomaly suggested that a multi well drilling opportunity mightexist. Although this well will likely be completed as a producingwell the results of the drilling have negated the ultimatepotential of the Hayter property.
About the Purchase of Interest in the Hayter Well
On August 1, 2006, County Line Energy Corp. ("County Line") signeda participation agreement with Black Creek Resources Ltd. ("BCR")in which County Line acquired the right to become the operator anddrill the Hayter well (10D Hayter 10-8-40-1 W4M) located inAlberta, Canada. In order to exercise that interest and acquire therights to drill the Hayter well, County Line agreed to pay 100% ofall costs associated with the seismic option agreement and pay 100%of the funds required to purchase rights to any existing seismic onthe property which may be for sale and or shoot additional 2D and3D on the property as required, pursuant to standard industry costsand practices.
Pursuant to a Participation Agreement dated December 21, 2006between Black Creek Resources Ltd ("BCR") and Nuance ExplorationLtd. ("NEL"), a wholly owned subsidiary of the Company, we acquireda 100% ownership in the interpretation of 3D seismic data coveringfour sections of certain land located in the province of Alberta,Canada by paying $82,650 for the purpose of acquiring andinterpreting the seismic data. On October 15, 2007, prior to theevaluation of the 3D seismic data, County Line sold to BCR its 100%interest in the subject property and received as consideration anon-interest bearing promissory note for $111,144 (CDN$110,000) tobe repaid by November 30, 2007.
On November 30, 2007, County Line did not repay the amounts owingpursuant to the promissory note and NEL and County Line enteredinto a Participation Agreement whereby NEL accepted a 20% interestof the Grantor's working interest in the County Line 10D Hayter10-8-40-1 W4M well as full and final settlement of the promissorynote. Pursuant to the terms of the Participation agreement NEL willassume 20% of all revenues, costs and expenses associated with theproject.
About Force Energy Corp.
Force Energy Corp. is an Oil & Gas Exploration and DevelopmentCompany based in Denver, CO with a focus on Wyoming. Using ageology-based methodology, the US Geological Survey estimate a meanof 2.4 trillion cubic feet of undiscovered natural gas, a mean of41 million barrels of undiscovered oil, and a mean of 20.5 millionbarrels of undiscovered natural gas liquids in the Wind River BasinProvince of Wyoming. They further estimate a mean of 84.6 trillioncubic feet of undiscovered natural gas, a mean of 131 millionbarrels of undiscovered oil, and a mean of 2.6 billion barrels ofundiscovered natural gas liquids in the Southwestern WyomingProvince. Force Energy Corp. has entered into LOI's to drill anddevelop two prospects located within each of these prolific areas.The Company's shares are publicly traded on the OTCBB under theticker symbol FORC.
July 22, 2008 -- GeoVax Labs, Inc. (OTCBB: GOVX), an Atlanta based,biopharmaceutical company developing human vaccines for diseasescaused by HIV-1 (Human Immunodeficiency Virus) and other infectiousagents, together with Vivalis (NYSE Euronext: VLS), a Frenchbiopharmaceutical company that provides innovative cell-basedsolutions to the pharmaceutical industry for the manufacture ofvaccines and proteins, announced today the signing of a letter ofintent (LOI) for joint collaboration and commercial license on theuse of Vivalis' EBx(R) technology, to manufacture the MVA componentof the GeoVax HIV-1 vaccine.
This agreement between GeoVax and Vivalis creates a worldwidestrategic partnership between Vivalis and GeoVax, designed tocombine Vivalis' cutting-edge vaccine manufacturing technology withGeoVax's promising HIV vaccine.
The breakthrough manufacturing technology developed by Vivalis, andnow to be further developed through collaboration with GeoVax, willcreate a new standard for manufacture of the MVA component of theGeoVax HIV/AIDS vaccine, making present manufacturing technologieswhich have limited production capabilities, less competitive.Vivalis' EBx(R) manufacturing platform, with its increasedeffectiveness, superior quality and reliability, will speed time tomarket MVA vaccine product availability in ample quantities to meetsizeable demand and expectedly at a lesser cost.
"Partnering with Vivalis and its cutting-edge technology isextremely significant, and a giant step forward for efficientmanufacturing of our 'MVA' HIV/AIDS vaccine component," statedRobert McNally, President and CEO, GeoVax.
"Vivalis is pleased to enter in this collaboration with GeoVax, oneof the most advanced companies worldwide in the field of HIVvaccine development. This agreement aims at developing a Vivalisproprietary upstream-downstream process for the production of MVAvaccines and EBx(R) technology licensing. GeoVax becomes astrategic partner and joins an elite worldwide consortium in thefield of development, purification and production of MVA basedvaccines," said Franck Grimaud, Vivalis CEO.
The EB66(R) cell line is becoming a new standard for the productionof vaccines, leading to Vivalis having signed more than 20 licensesprior to December 2007 and four licenses in 2008: two research andtwo commercial.
Vivalis' vaccine manufacturing technology is based on a duckembryonic stem cell substrate platform. The EB66(R) cell lineprovides continuous growth from a fully characterized frozen cellbank, without necessitating fertilized embryo extraction andprocessing, as with present chicken cell based technologies.Furthermore, the EB66(R) cell line can be grown in suspension(without the cells attached to the surface of the growth vessel)and can be scaled up for growth in giant bioreactors (a cuttingedge industrial method) for large scale production of the MVA viralvaccine.
Last month, Vivalis announced the filing of the BMF (BiologicsMaster File) for the EB66(R) cell line with the US FDA (Food andDrug Administration). Extensive testing reveals the unique andinnovative nature of Vivalis EBx(R) technology for the productionof vaccines and proteins. Today, the EB66(R) cell line is the onlyavailable cell line in the market to be immortal and diploid.
"When we learned about the work of Vivalis with EBx(R) cell linesthat might be able to be used to grow MVA, we contacted Vivalis andarranged with them to jointly conduct pilot studies on the growthof our MVA vaccine," said Harriet Robinson, Senior Vice Presidentof Research and Development, GeoVax. "Our early production resultshave been very promising and have led to this LOI for more formaldevelopment of the Vivalis EB66(R) cell line for the production ofour MVA vaccine."
The GeoVax vaccine is a DNA/MVA vaccine that uses recombinant DNAto prime the immune response and then a recombinant MVA virus toboost the immune response. MVA stands for Modified Vaccinia Ankara,a smallpox viral vaccine that was attenuated (made more safe) byreplicating the vaccine virus over 500 times in chicken cells. Thislong series of replications resulted in a derivative of thesmallpox vaccine virus which could grow in chicken cells but thathad limited ability to grow in human cells. The poor ability togrow on human cells has made MVA a very safe vaccine vector forhumans. However, it also limited the ability to manufacture MVA inthe industrial cell lines that have been approved for vaccineproduction. Rather, MVA had to be grown in chicken cells which relyon harvesting cells from thousands of chicken embryos and usingthese cells which are grown in multiple small vessels for vaccinemanufacture. This process can be done for clinical and commercialproduction, but is cumbersome, fraught by the introduction ofcontaminants and expensive. The Vivalis EBx(R) manufacturingtechnology eliminates such difficulties and enables rapid largescale production in bioreactors for GeoVax's future commercialneeds.
Financial terms of the agreement have not been disclosed. However,each side shall fund its roles respectively, depending ondevelopmental or process responsibilities assumed by each party. Anupfront amount payable to Vivalis will be provided as considerationfor the signing of the LOI. GeoVax's development and licensepayments shall be made based on milestone achievements. Royaltieson GeoVax net sales are also included. In addition, applicationshave been filed for EU and local government financialparticipation. GeoVax is also seeking FDA guidance on the VivalisEBx(R) manufacturing program recently submitted to the USA FDAallowing usage of EB66(R) produced MVA vaccine for GeoVax's ongoinghuman trials.
Earlier this month, GeoVax also announced an operational update onthe company's progress towards entering Phase 2 preventative humanclinical trial testing and plans to proceed into therapeutic humantrials with its AIDS vaccine. The Company's Phase 2 trial, to beconducted by the U.S. National Institutes of Health (NIH) andsupported HIV Vaccine Trials Network (HVTN), will involve 225healthy volunteers from the United States and South America, andwill further evaluate the safety and immunogenicity of the GeoVaxpreventative vaccine (vaccine administered prior to infection withthe AIDS virus). The GeoVax DNA/MVA vaccine uses a different viralvector (MVA) than the Merck vaccine and the NIH Vaccine ResearchCenter vaccines, which use adenovirus5 (Ad5) vectors. The Merckvaccine was withdrawn from trials in September 2007 because offailure to protect. The NIH has just announced that their vaccinewill not be progressing in large scale trials because of the Merckresults. Thus two major competitors for GeoVax are no longerprogressing in trials.
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established todevelop, manufacture, license and commercialize human vaccines fordiseases caused by HIV-1 (Human Immunodeficiency Virus) and otherinfectious agents. GeoVax's HIV/AIDS vaccine technology is thesubject of 20 issued or filed patent applications. GeoVax HIV/AIDSvaccines are designed for use in uninfected people to preventAcquired Immunodeficiency Disease (AIDS), caused by the virus knownas HIV-1, should the person ever become infected. GeoVax HIV/AIDSvaccines also may be effective as therapeutics (treatment of peoplealready infected with AIDS virus). Studies evaluating thesevaccines in HIV/AIDS infected individuals are in the planningstage.
GeoVax's core HIV/AIDS vaccine technologies were developed througha collaboration of colleagues at Emory University's Vaccine Center,the National Institutes of Health (NIH), The Centers for DiseaseControl and Prevention (CDC) and the GeoVax team.
GeoVax HIV/AIDS vaccines have moved forward in human clinicaltrials conducted by the HIV Vaccine Trials Network (HVTN) based inSeattle, Washington. The HVTN, funded through a cooperativeagreement with the National Institutes of Health (NIH), is thelargest worldwide clinical trials program dedicated to thedevelopment and testing of HIV/AIDS vaccines. Preclinical workenabling evaluation of GeoVax DNA and MVA vaccines was funded andsupported by NIAID, which provided additional support to GeoVaxAIDS vaccine development program with a $15 million IPCAVD grantawarded in late 2007.
About Vivalis
Vivalis (NYSE- Euronext: VLS) is a biopharmaceutical company thatprovides innovative cell-based solutions to the pharmaceuticalindustry for the manufacture of vaccines and proteins, and developsdrugs for the prevention and treatment of viral diseases. Vivalis'sexpertise and intellectual property are exploited in three mainareas:
1. The development and manufacturing of vaccines. Vivalis offersresearch and commercial licenses for its EB66(R) cell line, derivedfrom duck embryonic stem cells, to pharmaceutical and biotechnologycompanies for the production of viral vaccines. Vivalis receives upfront, milestones, and royalties on its licensees net sales.
2. The development of production systems for recombinant proteinsand monoclonal antibodies. Vivalis licenses its EB66(R) cell linefor the production of recombinant proteins to biotechnology andpharmaceutical companies. Vivalis receives up front, milestones,and royalties on its licensees net sales.
3. The construction of a portfolio of proprietary products in thearea of vaccines and anti-viral molecules (hepatitis C).
Jul 21, 2008 -- Hybred International, Inc.(OTC: HYII) wasestablished in 2005 and became a publicly traded company earlier inQ1 2008.
The Company believes it successfully created the next-generationtherapeutic horseshoe and is pleased to share the followinginformation.
Corporate Web Site:
www.hybredhorseshoe.com.
About the Hybred Horseshoe:
The Hybred Horseshoe was created to address the number one problemin the equine industry - hoof injuries which account for nearly 90%of all potentially serious and often detrimental injuries to horsesemployed in all sectors of the equestrian market.
The Hybred Horseshoe is comprised of a polyurethane molding whichonce attached to an aluminum horse shoe thus becomes a shockabsorber and protects the horse's hooves and joints fromdeterioration caused by running on hard surfaces such as concrete,asphalt and race tracks. In addition, its design features enablethe farrier the use traditional shoeing methods.
Primary Marketing Partner:
The Company has signed an agreement with Thoro'bred, the world'slargest manufacturer of horseshoes. Under the terms of theagreement, Thoro'bred will manufacture, market and distribute theHybred Horseshoe and market the product through itswell-established world-wide distribution network.
About the Equine Industry:
The equine industry is approximately a $39 Billion industryaccording to a study published in 2005 by Deloitte Consulting LLPfor the American Horse Council Foundation. Over 4.6 million peopleare engaged in the industry as horse owners, service providers,employees and volunteers; Tens of millions of other are spectatorsin equestrian events in one form or another.
The study also showed that the industry directly produces goods andservices of $38.8 Billion, with a total impact of $101.5 Billion onthe U.S. Gross Domestic Product.
About the Horse Shoe Market:
In the US alone, there are approximately 9 million horses thatrequiring shoeing each month. Considering that a shoeing is fourhorseshoes per horse each month for 9 million horses, the totalhorseshoe market in the United States is estimated at $432 millionper annum.
Based on the foregoing, the horse shoe industry, exclusive of anylabor and tooling, is approximately $3.2 Billion a year.
There are more than 52 million horses outside the United States,thus representing a potential market opportunity of an additional$18.7 Billion.
Jul 22, 2008 -- Invicta Group Inc. (OTCBB: IVIT) announces thelaunch of www.TicketHotLink.com, a new division to offer andprocess online ticket sales. Invicta group Inc. is blending itsonline traffic from over 50 websites, with its 25,000,000-emaildatabase, and the marketing power of its new marketing firm IMAGEWorldwide, Inc. (PINKSHEETS: IMGW) to offer a new online service.This year the Company expects revenues of around $25,000; $100,000in 2009 and $250,000 in 2010.
www.TicketHotLink.com allows online users to search 1000s of venuesfor 100,000s of tickets for sporting events, concerts, and otherspecial events.
Invicta's CEO Paul Sorkin said, "Ticket sales offer a perfecttie-in for our online users looking for travel packages that mayinclude airline tickets, hotel reservations, car rentals, and nowtickets to that special event. We are going to continue to launchnew divisions that will add to our bottom line over the comingmonths; with all of our divisions, we expect to see healthy growthover the coming months and years."
About IMAGE Worldwide, Inc.
IMAGE Worldwide, Inc. (PINKSHEETS: IMGW) is a full serviceinteractive multimedia marketing and advertising agency. IMAGE isvertically integrated with properties including a concert/nightclubvenue, fashion/entertainment magazine, high-end direct mailingbook, IT solutions company, along with other promotional andmarketing companies. IMAGE utilizes a combination of differentforms of media and promotions to help clients showcase and markettheir IMAGE in print, Internet, event planning, radio, and TV.
About Invicta Group Inc.


INVICTA GROUP INC. (OTCBB: IVIT) is an Internet Media Company thatspecializes in the Travel and Entertainment Industry. The companyhas a subsidiary that uses the Internet as their media to generaterevenues: Travel Hot Link links travel enthusiasts with products tofulfill their travel and entertainment needs. Travel Hot Link sellsits Internet database of 25 million travel enthusiasts to TravelSuppliers that want to promote their discounted travel products:airline tickets, hotel rooms, tour packages, rental cars, cruisecabins, and more on the Internet 24/7.
Jul 22, 2008 -- Rim Semiconductor Company (OTCBB: RSMI), a companythat develops technology for telecommunications service providers,announced today that it has reduced its indebtedness to itsconvertible note holders by 34% to $2,759,000, versus $4,182,000,as reported in its most recent 10QSB.
The reduction was effected when holders of its two-year 7% SeniorSecured Convertible Debentures and its two-year 10% SecuredConvertible Notes converted some of their principal and interestinto shares of Rim Semi's Common Stock. The company has 4 billionshares of common stock authorized for issuance. As of July 11,2008, following the issuance of the shares, the Company has issuedall of its authorized common stock. Since July 11th, the closingprice of RSMI has risen 100% from $0.0005 to $0.001 per share.
"I am very pleased that our convertible debt has reduced by 34%,"stated Brad Ketch, the company's president and chief executiveofficer. "We issued these shares to investors who have invested inus before, and who continue to show support for our long-termgrowth."
In addition to the debt reduction, the company projects that thevalue of the derivative liability on its balance sheet will alsoproportionately decline when the derivative liability calculationsare made at the end of the quarter, and based upon the closingprice of RSMI on July 31, 2008.
About Rim Semiconductor Company
Rim Semiconductor Company (OTCBB: RSMI) develops technology fortelecommunications companies to deliver demanding new video anddata services with lower network costs. The company's productsallow data to be transmitted at greater speed and across extendeddistances over existing copper wire--all with the highest qualityof service--for a better end-user experience.
About Standoutstocks.com
Standoutstocks.com has become one of the premier stops forinvestors who wish to experience huge profits via investing inup-and-coming publicly traded companies. Standoutstocks.com emailreport service is free to those investors who sign up on ourwebsite. The alert service is designed to notify investors ofundervalued and often overlooked stocks. Subscribers are introducedto OTCBB and Pinksheet companies that have the potential of showingincreased activity and Standing Out from the rest of the market. Tosubscribe to this free service, visit the Standout StocksReporthome page at www.Standoutstocks.com and select the "join now"button.
Join us at www.standoutstocks.com for a complimentary subscriptionto the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence.Standoutstocks.com profiles are not a solicitation orrecommendation to buy, sell or hold securities. Standoutstocks.comis not offering securities for sale. An offer to buy or sell can bemade only with accompanying disclosure documents and only in thestates and provinces for which they are approved. All statementsand expressions are the sole opinion of the editor and are subjectto change without notice. Standoutstocks.com is not liable for anyinvestment decisions by its readers or subscribers. It is stronglyrecommended that any purchase or sale decision be discussed with afinancial adviser, or a broker-dealer, or a member of any financialregulatory bodies. The information contained herein has beenprovided as an information service only. The accuracy orcompleteness of the information is not warranted and is only asreliable as the sources from which it was obtained. It should beunderstood there is no guarantee that past performance will beindicative of future results. Investors are cautioned that they maylose all or a portion of their investment in this or any othercompany. In order to be in full compliance with the Securities Actof 1933, Section 17(b), Standoutstocks.com is owned and operated byStandoutstocks.com. Neither Standoutstocks.com nor any of itsaffiliates, or employees shall be liable to you or anyone else forany loss or damages from use of this e-mail, caused in whole orpart by its negligence or contingencies beyond its control inprocuring, compiling, interpreting, reporting, or delivering thisWeb Site or e-mail and any contents. Since Standoutstocks.comreceives compensation and its employees or members of theirfamilies may hold stock in the profiled companies, there is aninherent conflict of interest in Standoutstocks.com statements andopinions and such statements and opinions cannot be consideredindependent. Standoutstocks.com and its management may benefit fromany increase in the share prices of the profiled companies.Information contained herein contains "forward looking statements"within the meaning of Section 27A of the Securities Act of 1933 andSection 21E of the Securities and Exchange Act of 1934. Anystatements that express or involve discussions with respect topredictions, expectations, beliefs, plans, projections, objectives,goals, assumptions or future events or performance are notstatements of historical facts and may be "forward lookingstatements". Forward looking statements are based on expectations,estimates and projections at the time the statements are made thatinvolve a number of risks and uncertainties which could causeactual results or events to differ materially from those presentlyanticipated. Standoutstocks.com services are often paid for usingfree-trading shares. Standoutstocks.com may be selling shares ofstock at the same time the profile is being disseminated topotential investors; this should be viewed as a definite conflictof interest and as such, the reader should take this intoconsideration.
Visit us for a full Disclaimer at:www.standoutstocks.com/disclaimer.aspx
CONTACT: StandoutStocks.com e-mail: info@standoutstocks.com WWW:http://www.standoutstocks.com
(M2 Communications Ltd disclaims all liability for informationprovided within M2 PressWIRE. Data supplied by named party/parties.Further information on M2 PressWIRE can be obtained athttp://www.presswire.net on the world wide web. Inquiries toinfo@m2.com).
Copyright 2008 M2 Communications Ltd.
Provider:
M2 Communications / M2 PressWIRE
Keywords:
Advertising & Public Relations , Business Management , Freight Transportation , U.S. Business News , Business News , Gas , Oil & Gas Exploration , Oil & Gas Market , Oil & Gas Retail Marketing & Sales , Non-U.S. Natural Gas Industry , Oil & Gas Tankers , Downstream Non-U.S. Natural Gas , Non-U.S. Oil Industry , Upstream Non-U.S. Oil , Front-Page Energy News , Oil & Gas , Upstream Gas , Top World News , Americas , North America , Transportation , Water Transportation , USA , Mass Media Strategic Alliances , Sales & Marketin